Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 5.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,718 shares of the company’s stock after selling 2,764 shares during the period. Victory Capital Management Inc.’s holdings in Arcus Biosciences were worth $681,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RCUS. Charles Schwab Investment Management Inc. boosted its stake in shares of Arcus Biosciences by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 579,623 shares of the company’s stock worth $8,631,000 after acquiring an additional 12,644 shares in the last quarter. US Bancorp DE increased its holdings in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Arcus Biosciences by 8.6% in the 4th quarter. Bank of New York Mellon Corp now owns 381,615 shares of the company’s stock valued at $5,682,000 after buying an additional 30,290 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Arcus Biosciences by 11.2% in the 4th quarter. Handelsbanken Fonder AB now owns 24,800 shares of the company’s stock worth $369,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Arcus Biosciences by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 263,517 shares of the company’s stock worth $3,924,000 after purchasing an additional 7,906 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Arcus Biosciences

In related news, Director Yasunori Kaneko bought 20,000 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares in the company, valued at $285,704. The trade was a 238.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Terry J. Rosen bought 19,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at $26,001,348.80. The trade was a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Arcus Biosciences Stock Performance

RCUS opened at $8.95 on Friday. The business’s 50-day moving average price is $11.66 and its two-hundred day moving average price is $14.62. Arcus Biosciences, Inc. has a 1 year low of $8.82 and a 1 year high of $19.11. The company has a market capitalization of $940.46 million, a price-to-earnings ratio of -2.84 and a beta of 1.36. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.14. The firm had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Equities analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on RCUS. Bank of America dropped their price objective on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Morgan Stanley dropped their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $30.25.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.